Infantile Spasm Treatment Market is estimated to surpass US$ 143.5 Million with CAGR of 3.1% by 2028 | H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc

Infantile spasm treatment are used for the treatment of seizures of an epilepsy syndrome in infants usually below 1 year.

An infantile spasm is a sudden jerking episode that affects the head, neck, arms, legs, or trunk. Depending on the severity of the spasm, it can affect a baby’s development or cause a delay in growth. An electroencephalogram can identify a number of conditions, but is often inconclusive when it comes to infantile spasms. Another test to help determine if infantile spasms are caused by a brain disorder is a video-electroencephalogram. In this test, electrodes are placed on the baby’s skull, and video is captured while the baby is in spasms.

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/2453

The global infantile spasm treatment market size was valued at US$ 111.1 million in 2017 and is expected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026).

Growing government initiatives for treatment of rare diseases to propel growth of the infantile spasm treatment market

Infantile spasm, also called as west syndrome, is a rare disorder that affects children below 1 year age. It is a sudden jerking episode that affects the head, neck, arms, legs, or trunk Seizures in children often appear as normal hiccups or body movement, and parents are unaware about the presence of this disease in their kid. Thus, to tackle this challenge, various governments and organizations are initiating programs to educate people about the disease. The government of China published a comprehensive list of rare diseases in 2018, in order to better identify the patients affected by rare disease and provide treatment for the same. Moreover, such initiatives will help to speed up the drug development process for rare diseases.

Growing birth rate could result in high prevalence of infantile spasm, which is projected to augment growth of the infantile spasms treatment market over the forecast period.

On the other, high cost of treatment, lack of proper diagnosis of infantile spasm, and stringent regulations for drug approval are some of the factors hindering the market growth. For instance, Acthar, which is a corticotropin branded product from Mallinckrodt pharmaceutical, costs around US$ 125,000 per patient, i.e. US$ 28,000 per dose

Growing adoption of infantile spasms treatment procedure in North America to bolster the market growth

North America holds leading position in the global infantile spasm treatment market, due to increasing adoption of infantile spasms treatment procedures and large scale research and development activities in this region. For instance, INSYS Therapeutics developed Cannabidiol in October 2012, Oral Solution for infantile spasm, which is under phase III clinical trial. The reoccurrence of infantile spasm is a major factor that boosts the market growth.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2453

Growing prevalence of central nervous system (CNS) infection can develop infantile spasm which is also expected to boost the market growth. In July 2012, the National Center for Biotechnology Information (NCBI) report stated that around 50% of infantile spasm cases in the U.S. have a prenatal cause, including central nervous system infection, intrauterine insults, neurologic disorders such as tuberous sclerosis complex (TSC), and genetic syndrome.

Additionally, approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) that helps in speedy approval by designating the orphan drug status to drugs targeted to benefit patients with rare disease is projected to boost the market growth.

Key Players

Key players operating in the global infantile spasm market include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.

Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2453

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Infantile Spasm Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Infantile Spasm Treatment Industry Impact

Chapter 2 Global Infantile Spasm Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Infantile Spasm Treatment (Volume and Value) by Type
2.3 Global Infantile Spasm Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Infantile Spasm Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Infantile Spasm Treatment Market Analysis
Chapter 6 East Asia Infantile Spasm Treatment Market Analysis
Chapter 7 Europe Infantile Spasm Treatment Market Analysis
Chapter 8 South Asia Infantile Spasm Treatment Market Analysis
Chapter 9 Southeast Asia Infantile Spasm Treatment Market Analysis
Chapter 10 Middle East Infantile Spasm Treatment Market Analysis
Chapter 11 Africa Infantile Spasm Treatment Market Analysis
Chapter 12 Oceania Infantile Spasm Treatment Market Analysis
Chapter 13 South America Infantile Spasm Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Infantile Spasm Treatment Business
Chapter 15 Global Infantile Spasm Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology

View Press Release: https://www.coherentmarketinsights.com/press-release/infantile-spasm-treatment-market-to-surpass-us-1435-million-by-2026-1259